ITCW3 Preconference Presentations

Modeling Intracellular Concentrations with In Vitro Imaging and Liver Perfusion Studies
Ken Korzekwa, PhD
Temple University School of Pharmacy, Philadelphia, PA

Is Prediction of Tissue Exposure from In Vitro Data Using PBPK Modeling Possible? Confirmation by PET Imaging to Study the Clinical Disposition of Membrane Transporter Substrates
Yuichi Sugiyama, PhD
RIKEN, Yokohama, Japan

OATP2B1: In Vitro, Proteomic, and Clinical PK Relevance in GI and Liver
Jashvant D. Unadkat, PhD
University of Washington, Seattle, WA

Inhibitor Discovery for the Human GLUT1 from Homology Modeling and Virtual Screening
Avner Schlessinger, PhD
Icahn School of Medicine atMount Sinai, New York, NY

PBPK Modeling of Renal Impairment: What is Missing?
Aleksandra Galetin, PhD
University of Manchester, Manchester, United Kingdom

Na+/Citrate Transporter [SLC13A5] Variants in Epilepsy and Developmental Delay
Ana M. Pajor, PhD
University of California, San Diego, La Jolla, CA

Endogenous Biomarker fo OATP1B: Preclinical to Clinical Translation
Yurong Lai, MD, PhD
Gilead Sciences, Foster City, CA

A European Perspective
Eva Gil Berglund, PhD
Medical Products Agency, Uppsala, Sweden

Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physioloigically-Based Pharmacokinetic Model
Imad Hanna
Novartis Institutes for Biomedical Research, East Hanover, NJ

IVIVE of Transporter-Mediated Clinical Drug-Drug Interactions in Industry –An Update from the IQ Transporter Working Group 
Kari Morrissey 

Emerging Importance of Nutrient Transporter-Mediated DDIs--focusing on the thiamine transporters
Yan Zhang, PhD
Incyte Corpration

Induction: Drug Transporters versus Enzymes
Justin D. Lutz
Gilead Sciences, Inc., Foster City, CA

Panel Discussion with Academic, Industry, and Regulatory Scientists
Joseph Polli, PhD
GlaxoSmithKline, King of Prussia, PA

528 N Washington St, Alexandria, VA 22314 |  Ph: 703.836.6981 |